A kind of papaya proanthocyanidin and its preparation method and application

By extracting and isolating papaya proanthocyanins from papaya, the problem of incomplete research on anti-inflammatory components in papaya in the prior art is solved, and high purity and high yield of anti-inflammatory components are achieved, and new ways to prepare anti-inflammatory drugs are provided. and demonstrated significant anti-inflammatory effects.

CN116120336BActive Publication Date: 2024-11-19JIANGNAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310134816.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-17
Publication Date
2024-11-19
Estimated Expiration
2043-02-17

AI Technical Summary

Technical Problem

Existing research has not yet fully understood the other anti-inflammatory components in papaya except malic acid and citric acid, which have affected the development of inflammation treatment.

Method used

A new compound was extracted and isolated from papaya by aqueous ethanol extraction and multiple chromatographic separation techniques, named papaya proanthocyanin, and its purity and yield were improved by column chromatography and gradient elution techniques.

Benefits of technology

Papaya proanthocyanin was successfully extracted, with a yield of 74.89% and a purity of 98.04%. It was determined that it was one of the main anti-inflammatory components in papaya, providing a new way to prepare anti-inflammatory drugs, significantly inhibiting the swelling and swelling of the animal ears. rate, demonstrated significant anti-inflammatory effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116120336B_ABST
    Figure CN116120336B_ABST
Patent Text Reader

Abstract

The present invention discloses a papaya proanthocyanidin and a preparation method and application thereof, and belongs to the technical field of chemical food and medicine. The present invention provides a new compound shown in formula I, and extracts and separates papaya proanthocyanidin with the structure shown in formula I from papaya for the first time, with a yield of 74.89% and a purity of 98.04%. The new compound shown in formula I of the present invention has anti-inflammatory effect, and provides a new way to prepare anti-inflammatory drugs. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to papaya proanthocyanidin and a preparation method and application thereof, belonging to the technical field of chemical food and medicine. Background Art

[0002] Papaya, the fruit of Chaenomeles speciasa (sweet) Nakai, a plant of the Rosaceae family, is a medicinal and edible material with the effects of removing dampness and relieving arthralgia, relaxing muscles and tendons, and expelling wind and activating blood circulation. Pharmacological studies have shown that papaya has anti-inflammatory, analgesic, antibacterial and antioxidant effects. Papaya contains a large number of organic acids, including chlorogenic acid, tartaric acid, ursolic acid and oleanolic acid in addition to malic acid and citric acid. It is generally believed that total organic acids have good anti-inflammatory and analgesic effects. However, papaya has a complex composition, and current research is not mature and sufficient. It is unknown whether there are other substances with anti-inflammatory effects, which is also of great significance to the development of inflammation treatment. Summary of the invention

[0003] The present invention extracts and separates a new compound from papaya for the first time, which is named papaya proanthocyanidin, and determines that the compound is also one of the anti-inflammatory components in papaya.

[0004] The invention adopts aqueous ethanol extraction and multiple chromatography separation to extract and separate a new compound, papaya proanthocyanidin, from papaya, and finds that the new compound has good anti-inflammatory effect.

[0005] The first object of the present invention is to provide a compound having a structure shown in Formula I or a pharmaceutically acceptable salt thereof,

[0006]

[0007] In one embodiment of the present invention, the pharmaceutically acceptable salt includes an inorganic salt or an organic salt; the inorganic salt includes hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, bisulfate, nitrate, phosphate, and acid phosphate; the organic salt is selected from formates, acetates, trifluoroacetates, propionates, pyruvates, glycolates, oxalates, malonates, succinates, glutarates, fumarates, maleates, lactates, malates, citrates, tartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, salicylates, p-toluenesulfonates, and ascorbates.

[0008] The present invention also provides a method for preparing the compound of the structure shown in the above formula I, comprising the following steps:

[0009] (1) Extraction: Crush the papaya, add aqueous ethanol for extraction, filter, take the clear liquid, and concentrate it under reduced pressure to 15-20% volume to obtain the papaya extract concentrate.

[0010] (2) Separation: The papaya extract concentrate obtained in step (1) is subjected to column chromatography and eluted with water and ethanol solutions of different concentrations to obtain proanthocyanidins.

[0011] In one embodiment of the present invention, the compound with the structure shown in the above formula I is a new proanthocyanidin, named papaya proanthocyanidin.

[0012] In one embodiment of the present invention, step (1) in the preparation method specifically comprises:

[0013] Crush the papaya peel into small pieces with a diameter of less than 5 mm, add 0-60% aqueous ethanol, stir and extract at a temperature below 60°C for 3 hours, filter, take the clear liquid, extract twice, combine the filtrate, and concentrate under reduced pressure to 15-20% volume to obtain papaya extract concentrate.

[0014] In one embodiment of the present invention, step (2) in the preparation method specifically comprises:

[0015] The papaya extract concentrate is loaded onto an AB-8 macroporous resin chromatography column, and gradient elution is performed with deionized water, 10%, 20%, 30%, and 50% ethanol aqueous solutions in sequence, with one column volume for each gradient elution, the proanthocyanidins are concentrated in the 30% ethanol eluate, the 30% ethanol aqueous solution elution portion is collected, and after reduced pressure concentration, the proanthocyanidins are loaded onto a Sephadex LH-20 chromatography column, and gradient elution is performed with deionized water, 5%, 10%, 20%, and 30% ethanol aqueous solutions in sequence, with one column volume for each gradient elution, the proanthocyanidins are concentrated in the 10% ethanol eluate, the 10% ethanol aqueous solution elution portion is collected, and after reduced pressure concentration, the proanthocyanidins are loaded onto an ODS-AQ chromatography column, and gradient elution is performed with deionized water, 5%, 10%, and 15% ethanol by volume, with one column volume for each gradient elution, the 15% ethanol elution portion is collected, concentrated, and dried to obtain a proanthocyanidin product.

[0016] The present invention also provides the use of the compound with the structure shown in the above formula I in the preparation of anti-inflammatory drugs.

[0017] The present invention also provides an anti-inflammatory drug containing the compound having the structure shown in the above formula I.

[0018] In one embodiment of the present invention, the anti-inflammatory drug also includes pharmaceutical excipients; the pharmaceutical excipients include: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, flocculants and deflocculating agents, filter aids and release retardants.

[0019] In one embodiment of the present invention, the anti-inflammatory drug further comprises a pharmaceutical carrier; the pharmaceutical carrier is selected from microcapsules, microspheres, nanoparticles and liposomes.

[0020] In one embodiment of the present invention, the dosage forms of the anti-inflammatory drug include injections, suspensions, implants, embolic agents, capsules, tablets, pills and oral solutions.

[0021] Beneficial effects:

[0022] The present invention extracts and separates a new structure of proanthocyanidin from papaya for the first time, with a yield of 74.89% and a purity of 98.04%. The present invention also determines that the new proanthocyanidin is one of the main anti-inflammatory components in papaya, providing a new way to prepare anti-inflammatory drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The papaya proanthocyanidin of the structure shown in formula I 13 C-NMR spectrum;

[0024] Figure 2 The papaya proanthocyanidin of the structure shown in formula I 135 DEPT-NMR diagram. DETAILED DESCRIPTION

[0025] Example 1 Preparation of the compound represented by formula I

[0026]

[0027] The compound shown in formula I was prepared by extracting from papaya:

[0028] 5 kg of fresh papaya, without peeling, cut in half, remove the seeds, and break into small pieces with a diameter of less than 5 mm. Put all the crushed pulp and juice into a 50-liter extraction tank, add 30 liters of 45% ethanol aqueous solution, stir and extract at 50°C for 3 hours, stir at 120 rpm, filter, take the clear liquid, extract twice, combine the filtrate to obtain 57 liters, and concentrate under reduced pressure to 8 liters to obtain 45% ethanol extract concentrate of papaya.

[0029] 8 liters of papaya extract concentrate was placed on an AB-8 macroporous resin chromatography column (150×10 cm), first washed with 12 liters of deionized water, then gradient eluted with 12 liters of 10%, 20%, 30%, and 50% ethanol aqueous solutions, respectively, and the 30% ethanol aqueous solution elution portion was collected. The 30% ethanol aqueous solution elution portion was concentrated to 500 mL and then placed on a Sephadex LH-20 chromatography column, and then washed with deionized water, 5%, 10%, 20%, 30%, and 50% respectively. % ethanol aqueous solution for gradient elution, each gradient elution of 1 column volume, after detection, proanthocyanidins are concentrated in the 10% ethanol eluate, the 10% eluted ethanol aqueous solution is collected and desolventized, and then loaded onto an ODS-AQ chromatography column (100×5cm), and gradient elution is performed with deionized water, 5%, 10%, and 15% ethanol by volume, each gradient elution of 1 column volume, and the 15% ethanol elution part is collected, concentrated, and dried to obtain 31.1 grams of proanthocyanidins product. The compound product is a colorless amorphous powder, easily soluble in water, aqueous methanol, and ethanol.

[0030] The yield of the obtained proanthocyanidins was determined by HPLC to be 74.89% and the purity was 98.04%.

[0031] For the HPLC determination method, please refer to: Food Science, 2015, Vol.36, 146, Determination of the content of proanthocyanidins in lotus seed shell extract by HPLC.

[0032] The structure of the obtained substance was identified by nuclear magnetic resonance:

[0033] 1 H-NMR (500MHz, D2O) δ6.81(1H,s,),6.64(1H,d,J=8.5),6.58(1H,d,J=6.5s),6.56(1H,d,J=8.5),6.54(1H,d,J=6.5),6.45(1 H,s), 6.34(1H,s), 4.96(1H,s).4.22(1H,s), 3.77(1H,s),3.75(1H,s),3.72(1H,s), 2.80(1H,d,J=9.0).2.23(1H,d,J=9.0).

[0034] 13C-NMR (500MHz, D2O) δ158.1, 157.2, 157.1, 156.9, 155.9, 155.7, 146.5, 146.4, 146.2, 146.1, 133.9, 132.9, 123. 3, 121.9, 118.6, 118.3, 117.9, 117.3, 110.3, 105.6, 104.4, 98.2, 97.4, 97.2, 83.9, 77.9, 73.9, 70.0, 38.2, 31.2.

[0035] from 13 C-NMR shows that the compound is composed of catechin and epicatechin. HMBC shows that δH 3.72 is correlated with δC110.3, indicating that catechin and epicatechin are connected by C4-C8”. If it is just this connection, C6 and C6” should be CH signals, but from the 135dept spectrum, δ98.2 and 97.2 are both quaternary carbons, indicating that these two carbons are also bonded. Further analysis shows that C6-C6” is also connected, and since C6 and C6” are near quaternary carbons, HMBC fails to observe relevant signals, which is consistent with the structure.

[0036] The corresponding attribution information is shown in Table 1.

[0037]

[0038] Table 1 Product proanthocyanidins 1 H and 13 C NMR data

[0039]

[0040]

[0041] Example 2 Testing the anti-inflammatory efficacy of the compound of formula I

[0042] Fifty four-week-old SPF mice were purchased and fed adaptively for 7 days at a temperature of 25°C, a relative humidity of 50%, and an animal illumination of 15LX. They were randomly divided into a blank group, a positive control group, and an experimental group. The experimental groups were a papaya 20% ethanol extract group and a papaya proanthocyanidin group, with 10 mice in each group, half male and half female. The papaya extract group was gavaged at a dose of 1.0g / (kg·d), the papaya proanthocyanidin group was gavaged at a dose of 0.5g / (kg·d), and dexamethasone was administered as a positive control group at a dose of 10mg / (kg·d). The blank group was given normal drinking water for 7 consecutive days. One hour after the last administration, 20 μL of xylene was evenly dripped into the right ear of each group of mice, and no xylene was applied to the left ear as a control. After 30 minutes of xylene dripping, the mice were killed one by one, their ears were cut off along the auricle baseline, and holes were punched in the same part of the ears with a puncher to obtain ear discs of the same size, which were immediately weighed and recorded. The difference in weight between the two ear discs of the same mouse indicated the degree of swelling, and the ear swelling rate and ear swelling inhibition rate were calculated.

[0043] The 20% ethanol extract of papaya is prepared by the following method: 5 kg of fresh papaya is cut into half without peeling, the seeds are removed, and the pieces are broken into small pieces with a diameter less than 5 mm, the broken pulp and juice are all put into a 50L extraction tank, 20L of 50% ethanol aqueous solution is added, the mixture is stirred and extracted at 50°C for 3 hours, the mixture is stirred at 150 rpm, the mixture is filtered, the clear liquid is taken, the mixture is extracted twice, 36 liters of filtrate are combined, and the mixture is concentrated under reduced pressure to 8L to obtain the 20% ethanol extract of papaya. The 8L ethanol extract of papaya is put on an AB-8 macroporous resin chromatography column (150×10 cm), first washed with 12 liters of deionized water, and then gradient eluted with 12 liters of ethanol aqueous solution with a volume fraction of 10%, 20%, 30%, and 50% in sequence, and the 20% ethanol aqueous solution elution portion is collected to obtain the 20% ethanol extract of papaya.

[0044] Table 2 Anti-inflammatory effect of papaya extract

[0045]

[0046] Note: Compared with the blank group, *P<0.05, **P<0.01.

[0047] From Table 2, it can be seen that the papaya 20% ethanol extract group and the papaya proanthocyanidin group can significantly inhibit the ear swelling degree and swelling rate of animals, and have a significant anti-inflammatory effect. It is further concluded that proanthocyanidins play an important role in the anti-inflammatory effect of papaya.

[0048] The embodiments provided above are not intended to limit the scope of the present invention, and the steps described are not intended to limit the execution order thereof. Those skilled in the art may make obvious improvements to the present invention in combination with existing common knowledge, which also fall within the scope of protection defined by the claims of the present invention.

Claims

1. A compound of formula I or a pharmaceutically acceptable salt thereof, 2. A compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, It is characterized in that The pharmaceutically acceptable salt includes inorganic salts or organic salts; wherein the inorganic salt includes hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, bisulfate, nitrate, phosphate, acid phosphate; the organic salt is selected from formates, acetates, trifluoroacetates, propionates, pyruvates, glycolates, oxalates, malonates, succinates, glutarates, fumarates, maleates, lactates, malates, citrates, tartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, salicylates, p-toluenesulfonates, and ascorbates.

3. Use of the compound of formula I according to claim 1 or its pharmaceutically acceptable salt in the preparation of anti-inflammatory drugs.

4. An anti-inflammatory drug containing a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof.

5. The anti-inflammatory drug according to claim 4, It is characterized in that Anti-inflammatory drugs also include pharmaceutical excipients; the pharmaceutical excipients include: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesives, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, flocculants and deflocculating agents, filter aids and release retardants.

6. The anti-inflammatory drug according to claim 4, It is characterized in that The anti-inflammatory drug also includes a pharmaceutical carrier; the pharmaceutical carrier is selected from microcapsules, microspheres, nanoparticles and liposomes.

7. The anti-inflammatory drug according to claim 4, It is characterized in that Dosage forms of anti-inflammatory drugs include injections, suspensions, implants, embolics, capsules, tablets, pills and oral solutions.

8. A method for preparing the compound of formula I according to claim 1, It is characterized in that The following steps are involved: (1) Extraction: crush the papaya peel into small pieces with a diameter of less than 5 mm, add 0-60% aqueous ethanol, stir and extract at a temperature less than 60° C. for 3 hours, filter, take the clear liquid, extract twice, combine the filtrate, and concentrate under reduced pressure to 15-20% volume to obtain a papaya extract concentrate; (2) Separation: The papaya extract concentrate is loaded onto an AB-8 macroporous resin chromatography column, and gradient elution is performed with deionized water, 10%, 20%, 30%, and 50% ethanol aqueous solutions in sequence, with each gradient elution lasting 1 column volume. The proanthocyanidins are concentrated in the 30% ethanol eluate, and the 30% ethanol aqueous solution elution portion is collected. After reduced pressure concentration, the sample is loaded onto a Sephadex LH-20 chromatography column, and gradient elution is performed with deionized water, 5%, 10%, 20%, and 30% ethanol aqueous solutions in sequence, with each gradient elution lasting 1 column volume. The proanthocyanidins are concentrated in the 10% ethanol eluate, and the 10% ethanol aqueous solution elution portion is collected. After reduced pressure concentration, the sample is loaded onto an ODS-AQ chromatography column, and gradient elution is performed with deionized water, 5%, 10%, and 15% ethanol by volume in sequence, with each gradient elution lasting 1 column volume. The 15% ethanol elution portion is collected, concentrated, and dried to obtain the proanthocyanidin product.